= Zometa zoledronic acid (a bisphosphonate) Information: New study shows once again increase our value and effectiveness of Zometa = zoledronic acid compared with APD injections for bone problems of cancer patients

dated January 8, 2004: Source: Semin Oncol. December 2004, 31 (6 Suppl 12) :23-30.

New study shows higher value and re = efectiviteit of Zometa zoledronic acid compared with APD injections on bone problems including breast cancer , prostate cancer and Kahler - Multiple Myeloma

Optimizing bisphosphonates therapy in patient with breast cancer on endocrine therapy.
Harvey HA. Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, USA.

Deterioration of bone health is a major concern consistently progression and treatment of Patients with breast cancer, Especially in postmenopausal women. Disease-and treatment-associated skeletal-related events include fractures, spinal compression, bone pain, and hypercalcemia of malignancy. Bisphosphonates, Which inhibit osteoclastic bone resorption, are important new agents in the management of skeletal-related events, and Their Impact on breast cancer-related bone metastases and bone loss consistently on long-term estrogen deprivation therapies Such As aromatase inhibitors is reviewed. Intravenous bisphosphonates pamidronate HAS become the standard to reducing or delay Skeletal Complications of advanced breast cancer bone metastases, but the more potent agent, zoledronic acid, Appears to be at least as effective. Another agent, ibandronate, Also is active but not bone HAS Investigated in comparison with the Other intravenous bisphosphonates. Zoledronic acid is the must convenient to Administer, or require only a short infusion. The effects of bisphosphonates on bone health in women with early breast cancer are being Investigated Also. A single yearly infusion of zoledronic acid significantly Has Been Shown to Increase bone mineral density in postmenopausal osteoporotic women and to reducing biochemical markers of bone turnover. The Possibility of reversing Such treatment-aromatase inhibitor-associated bone loss consistently adjuvant therapy of breast cancer is being Evaluated in a trial of letrozole, with zoledronic acid added initially or after the onset of bone loss or fracture.

PMID: 15719598 [PubMed - indexed for MEDLINE]